Paper Details

  1. Home
  2. Paper Details

Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry.

Author: CaiWeikang, ChenHongyin, ChenPin, ChenSifan, DengKai, FanDongxiao, GuLei, GuanDongxian, GuoZeling, HeXi, HuAo, HuangBingding, HuangKan, LiJiuzhou, LiLinghua, LiWenxue, LiYihui, LiZilun, LinFen, LiuChenshu, LiuJiang, LuYutong, LuoHengli, PengJiangyun, PengMeixiu, YanLi, ZhangYang, ZhangYixin, ZhangZefeng, ZhuWei, ZhuYuanyuan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study identified imatinib, methazolamide, and harpagoside as direct activators of the ACE2 pathway, which is impaired in COVID-19 and contributes to metabolic complications. These compounds improved metabolic perturbations in vivo in both insulin-resistant and SARS-CoV-2-infected states. Additionally, they inhibited viral entry by allosterically inhibiting ACE2 binding to the spike protein on SARS-CoV-2. This research suggests that enzymatic activation of ACE2 may represent a novel therapeutic approach for treating metabolic sequelae of COVID-19.
Paper Details　
Original Abstract of the Article :
Coronavirus disease 2019 (COVID-19) represents a systemic disease that may cause severe metabolic complications in multiple tissues including liver, kidney, and cardiovascular system. However, the underlying mechanisms and optimal treatment remain elusive. Our study shows that impairment of ACE2 pat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832557/

データ提供：米国国立医学図書館（NLM）

Unveiling a New Frontier in COVID-19 Treatment: Imatinib, Methazolamide, and the ACE2 Pathway

This research explores the intriguing link between COVID-19 infection and metabolic complications, shedding light on a potential therapeutic strategy targeting the ACE2 pathway. The authors demonstrate that impairment of the ACE2 pathway plays a crucial role in connecting viral infection to metabolic disturbances in various tissues. Through a combination of computational and experimental approaches, the study identified imatinib, methazolamide, and harpagoside as potential activators of ACE2 enzymatic activity. Furthermore, the study found that these compounds directly inhibited viral entry, suggesting a dual mechanism of action.

Re-Energizing ACE2: A Potential Key to Combatting COVID-19's Metabolic Effects

The study's findings suggest that imatinib and methazolamide may have a beneficial effect on metabolic perturbations associated with COVID-19, potentially acting through their ability to enhance ACE2 activity. This discovery opens a promising avenue for developing novel treatment strategies for COVID-19-related metabolic complications.

Unlocking the Potential of ACE2: A Glimpse into the Future

This research offers hope for mitigating the metabolic consequences of COVID-19. The study's exploration of the ACE2 pathway as a therapeutic target holds potential for improving patient outcomes. Further research is needed to fully understand the efficacy and safety of these compounds in treating COVID-19, but this study provides a promising starting point.

Dr. Camel's Conclusion

Like a camel seeking a hidden oasis in the desert, this research delves into the depths of COVID-19's impact on metabolism, uncovering potential therapeutic strategies targeting the ACE2 pathway. This research offers hope for a brighter future in combating the complex challenges posed by this global pandemic.

Date :
  1. Date Completed 2022-03-09
  2. Date Revised 2023-03-15
Further Info :

Pubmed ID

35150639

DOI: Digital Object Identifier

PMC8832557

Related Literature

Article Analysis
・Effects of methazolamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.